NASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free avbp Stock Alerts $17.36 +0.11 (+0.64%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$16.82▼$17.8550-Day Range$15.30▼$22.7552-Week Range$14.35▼$25.95Volume40,811 shsAverage Volume181,918 shsMarket Capitalization$581.46 millionP/E RatioN/ADividend YieldN/APrice Target$29.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get ArriVent BioPharma alerts: Email Address ArriVent BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside68.5% Upside$29.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.11) to ($2.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.54 out of 5 starsMedical Sector665th out of 905 stocksPharmaceutical Preparations Industry308th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArriVent BioPharma has only been the subject of 4 research reports in the past 90 days.Read more about ArriVent BioPharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AVBP. Previous Next 0.0 Dividend Strength Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVBP. Previous Next 3.1 News and Social Media Coverage News SentimentArriVent BioPharma has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ArriVent BioPharma this week, compared to 3 articles on an average week.Search Interest2 people have searched for AVBP on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 9.48% of the stock of ArriVent BioPharma is held by institutions.Read more about ArriVent BioPharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ArriVent BioPharma are expected to grow in the coming year, from ($3.11) to ($2.63) per share.Read more about ArriVent BioPharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About ArriVent BioPharma Stock (NASDAQ:AVBP)ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Read More AVBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVBP Stock News HeadlinesMay 8, 2024 | investorplace.comAVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024May 8, 2024 | globenewswire.comArriVent BioPharma Reports First Quarter 2024 Financial ResultsMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 3, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for ArriVent BioPharma, Inc.'s Q1 2024 Earnings (NASDAQ:AVBP)May 1, 2024 | americanbankingnews.comArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at HC WainwrightMay 1, 2024 | nasdaq.comHC Wainwright & Co. Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationApril 22, 2024 | globenewswire.comArriVent Appoints Kristine Peterson to its Board of DirectorsApril 1, 2024 | markets.businessinsider.comBuy Rating on ArriVent BioPharma Highlighting Furmonertinib’s Potential in NSCLC Treatment LandscapeMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.March 29, 2024 | finanznachrichten.deArriVent BioPharma, Inc.: ArriVent BioPharma Reports Full Year 2023 Financial ResultsMarch 28, 2024 | businesswire.comInnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor FurmonertinibMarch 28, 2024 | msn.comArriVent BioPharma reports FY resultsMarch 28, 2024 | globenewswire.comArriVent BioPharma Reports Full Year 2023 Financial ResultsMarch 6, 2024 | uk.investing.comArrivent Biopharma Inc (AVBP)March 5, 2024 | markets.businessinsider.comBuy Rating on ArriVent BioPharma: Advancing NSCLC Treatment with Promising Furmonertinib ProspectsSee More Headlines Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/08/2024Next Earnings (Estimated)6/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CUSIPN/A CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$29.25 High Stock Price Target$35.00 Low Stock Price Target$25.00 Potential Upside/Downside+68.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.76 Quick Ratio13.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.79) per share Price / Book-3.62Miscellaneous Outstanding Shares33,494,000Free FloatN/AMarket Cap$581.46 million OptionableN/A BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Zhengbin Yao Ph.D. (Age 58)Co-Founder, Chairman, President & CEO Comp: $791.09kDr. Stuart Lutzker M.D. (Age 63)Ph.D., Co-Founder, President of Research & Development and Director Comp: $709.43kMs. Robin LaChapelle M.A. (Age 51)Co-Founder & COO Comp: $586.45kMr. Winston Kung M.B.A. (Age 48)CFO & Treasurer Ms. Yang Wang Ph.D.Chief Technology OfficerMr. James Paul Kastenmayer J.D. (Age 52)Ph.D., General Counsel & Secretary Dr. Dandan Dong (Age 39)Chief Business Officer Ms. Meghna ChowdarySenior Vice President of Commercial StrategyMore ExecutivesKey CompetitorsOlema PharmaceuticalsNASDAQ:OLMAIGM BiosciencesNASDAQ:IGMSPhathom PharmaceuticalsNASDAQ:PHATGH ResearchNASDAQ:GHRSAerovate TherapeuticsNASDAQ:AVTEView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 4,659 shares on 5/1/2024Ownership: 0.014%Hillhouse Investment ManagemenBought 555,555 shares on 1/30/2024Total: $10.00 M ($18.00/share)Orbimed Advisors LlcBought 444,444 shares on 1/30/2024Total: $8.00 M ($18.00/share)View All Insider TransactionsView All Institutional Transactions AVBP Stock Analysis - Frequently Asked Questions Should I buy or sell ArriVent BioPharma stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ArriVent BioPharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVBP shares. View AVBP analyst ratings or view top-rated stocks. What is ArriVent BioPharma's stock price target for 2024? 4 brokers have issued twelve-month price objectives for ArriVent BioPharma's stock. Their AVBP share price targets range from $25.00 to $35.00. On average, they predict the company's stock price to reach $29.25 in the next twelve months. This suggests a possible upside of 68.5% from the stock's current price. View analysts price targets for AVBP or view top-rated stocks among Wall Street analysts. How have AVBP shares performed in 2024? ArriVent BioPharma's stock was trading at $20.00 at the beginning of 2024. Since then, AVBP stock has decreased by 13.2% and is now trading at $17.36. View the best growth stocks for 2024 here. When is ArriVent BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024. View our AVBP earnings forecast. When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an IPO on Friday, January 26th 2024. The company issued 9,722,222 shares at $18.00 per share. When does ArriVent BioPharma's lock-up period expire? ArriVent BioPharma's lock-up period expires on Wednesday, July 24th. ArriVent BioPharma had issued 9,722,222 shares in its IPO on January 26th. The total size of the offering was $174,999,996 based on an initial share price of $18.00. After the end of ArriVent BioPharma's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. Who are ArriVent BioPharma's major shareholders? ArriVent BioPharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BNP Paribas Financial Markets (0.01%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVBP) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
